Attached files
file | filename |
---|---|
EX-21.1 - EX-21.1 - Crinetics Pharmaceuticals, Inc. | d588296dex211.htm |
EX-10.9 - EX-10.9 - Crinetics Pharmaceuticals, Inc. | d588296dex109.htm |
EX-10.7 - EX-10.7 - Crinetics Pharmaceuticals, Inc. | d588296dex107.htm |
EX-10.6 - EX-10.6 - Crinetics Pharmaceuticals, Inc. | d588296dex106.htm |
EX-10.2 - EX-10.2 - Crinetics Pharmaceuticals, Inc. | d588296dex102.htm |
EX-10.1 - EX-10.1 - Crinetics Pharmaceuticals, Inc. | d588296dex101.htm |
EX-4.2 - EX-4.2 - Crinetics Pharmaceuticals, Inc. | d588296dex42.htm |
EX-3.2 - EX-3.2 - Crinetics Pharmaceuticals, Inc. | d588296dex32.htm |
EX-3.1 - EX-3.1 - Crinetics Pharmaceuticals, Inc. | d588296dex31.htm |
S-1 - S-1 - Crinetics Pharmaceuticals, Inc. | d588296ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Crinetics Pharmaceuticals, Inc.
San Diego, California
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May 2, 2018, relating to the consolidated financial statements of Crinetics Pharmaceuticals, Inc., which is contained in that Prospectus.
We also consent to the reference to us under the caption Experts in the Prospectus.
/s/BDO USA, LLP
San Diego, California
June 22, 2018